Pronounced inhibitory effect of chlorcyclizine (CCZ) in experimental hepatocarcinoma

Sujata G. Dastidar, Kumkum Ganguly, S. K. Mahapatra, Noton Kumar Dutta, Kaushiki Mazumdar, A. N. Chakrabarty, Noboru Motohashi

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

The piperazine chlorcyclizine HCl (CCZ), possessing significant antimetabolic as well as virucidal and virustatic activities against the human immunodeficiency virus (HIV) and other retroviruses, was selected to determine its anticarcinogenic potential. The anticancer activity of CCZ was evaluated against procarcinogen n-diethylnitrosamine (NDA)-initiated hepatocarcinogenesis, which was subsequently promoted by phenobarbital (PB) in male Sprague-Dawley rats. The anticancer efficacy of CCZ was monitored by estimating some potential markers of neoplastic and preneoplastic hepatic conditions, eg., glutathione (GSH), glutathione-S-transferase (GST) and γ-glutamyl transpeptidase (γGTP). CCZ ethibited antineoplastic activity on a long-term therapeutic basis. Furthermore, this drug restricted the exponential increase of the antioxidant markers in the hyperplastic nodule and the surrounding liver tissues in comparison with the carcinogen-controlled rats during the entire period of treatment. A decrease in the number of nodules was observed in the CCZ-treated group.

Original languageEnglish (US)
Pages (from-to)97-102
Number of pages6
JournalIn Vivo
Volume20
Issue number1
StatePublished - 2006
Externally publishedYes

Keywords

  • Carcinogenesis
  • Chlorcyclizine
  • Hepatocarcinoma
  • n-diethyl-nitrosamine

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology
  • Pharmacology

Fingerprint

Dive into the research topics of 'Pronounced inhibitory effect of chlorcyclizine (CCZ) in experimental hepatocarcinoma'. Together they form a unique fingerprint.

Cite this